A federal judge in Maine has put the brakes on a pilot program that would have enabled biopharma companies to offer rebates instead of discounts as part of the 340B program beginning Jan. 1, 2026.

Please listen to podcast here. In the latest episode of Health Law Diagnosed, Of Counsel Bridgette Keller is joined by Associate Hassan Shaikh for a discussion on noteworthy developments relating to ...

It’s no secret that for working families, the cost of healthcare has spiraled out of control. But much less known is the ...

Because Cassidy is chair of the Senate Health, Education, Labor, and Pensions committee, his opposition to the program could ...

This approach would aim to raise the same amount of revenue that was previously generated by covered entities’ arbitrage of 340B drugs without the perverse incentives perpetuated by the current ...

Although 340B does not operate through the tax code, its economic effects mirror those of a tax expenditure. Recognizing it as such would not prejudge the program’s merits but would force a ...

Readers offer opposing views on whether the healthcare program is living up to its mission.

Forbes contributors publish independent expert analyses and insights. I am a cable news contributor and professor of journalism. This voice experience is generated by AI. Learn more. This voice ...

For patients in Michigan living with a complex or chronic condition, home infusion therapy is a safe, comfortable and cost-effective way to receive essential treatments. As someone who works closely ...

(The Center Square) – Hospitals and clinics in Michigan participating in a federal drug discount program are marking up medications and shifting costs onto public employee health plans, according to a ...

For the second time, the Centers for Medicare & Medicaid Services (CMS) modified the Request for Applications (RFA) document for manufacturers, which sets forth the terms of the “GENErating cost ...